Exploiting clinical trial data drastically narrows the window of possible solutions to the problem of clinical adaptation of a multiscale cancer model

PLoS ONE

Volumn 6, Issue 3, 2011, Pages

  Stamatakos, Georgios S ^a   Georgiadi, Eleni C ^a   Graf, Norbert ^b   Kolokotroni, Eleni A ^a   Dionysiou, Dimitra D ^a  

^a NATIONAL TECHNICAL UNIVERSITY OF ATHENS   (Greece)

^b SAARLAND UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER MODEL; CANCER STEM CELL; CELL DIVISION; CLINICAL STUDY; CLINICAL TRIAL (TOPIC); DATA ANALYSIS; HISTOLOGY; MATHEMATICAL MODEL; NEPHROBLASTOMA; NUTRIENT AVAILABILITY; PREOPERATIVE TREATMENT; SENSITIVITY ANALYSIS; SOLID TUMOR; TISSUE OXYGENATION; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR VOLUME; VALIDATION PROCESS; ALGORITHM; BIOLOGICAL MODEL; CHILD; COMPUTER SIMULATION; HUMAN; METABOLISM; METHODOLOGY; PATHOLOGY; REPRODUCIBILITY; TIME; TRANSLATIONAL RESEARCH;

CYTOKINE;

ALGORITHMS; CHILD; CLINICAL TRIALS AS TOPIC; COMPUTER SIMULATION; CYTOKINES; HUMANS; MODELS, BIOLOGICAL; REPRODUCIBILITY OF RESULTS; TIME FACTORS; TRANSLATIONAL RESEARCH; TUMOR BURDEN; WILMS TUMOR;

EID: 79952307201     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0017594     Document Type: Article

References (51)

1. Anderson AR, Quaranta V, (2008) Integrative mathematical oncology. Nat Rev Cancer 8: 227-234.
2. Deisboeck TS, Zhang L, Yoon J, Costa J, (2009) In silico cancer modeling: is it ready for prime time? Nat Clin Pract Oncol 6 (1): 34-42.
3. Ventura AC, Jackson TL, Merajver SD, (2009) On the role of cell signaling models in cancer research. Cancer Res 69 (2): 400-402.
4. Enderling H, Chaplain MAJ, Anderson ARA, Vaidya JS, (2007) A mathematical model of breast cancer development, local treatment and recurrence. J Theor Biol 246: 245-259.
5. Powathil G, Kohandel M, Sivaloganathan S, Oza A, Milosevic M, (2007) Mathematical modeling of brain tumors: effects of radiotherapy and chemotherapy. Phys Med Biol 52: 3291-3306.
6. Rockne R, Alvord EC, Szeto M, Gu S, Chakraborty G, et al. (2008) Modeling diffusively invading brain tumors: an individualized approach to quantifying glioma evolution and response to therapy. In: Belomo N, Chaplain MAJ, Angelis E, editors. Selected topics in cancer modeling Birkhaeuser pp. 207-221.
7. Sottoriva A, Verhoeff J, Borovski T, McWeeney SK, Naumov L, et al. (2010) Cancer stem cell tumor model reveals invasive morphology and increased phenotypical heterogeneity. Cancer Res 70 (1): 46-56.
8. Frieboes HB, Zheng X, Sun C-H, Tromberg B, Gatenby R, et al. (2006) An integrated computational/experimental model of tumor invasion. Cancer Res 66 (3): 1597-1604.
9. Castorina P, Carcò D, Guiot C, Deisboeck TS, (2009) Tumor Growth Instability and Its Implications for Chemotherapy. Cancer Res 69 (21): 8507-15.
10. Duechting W, Ulmer W, Lehrig R, Ginsberg T, Dedeleit E, (1992) Computer simulation and modeling of tumor spheroids growth and their relevance to optimization of fractionated radiotherapy. Strahlenther Onkol 168 (6): 354-360.
11. Stamatakos GS, Dionysiou DD, Zacharaki EI, Mouravliansky NA, Nikita KS, et al. (2002) In silico radiation oncology: combining novel simulation algorithms with current visualization techniques. Proc IEEE 90 (11): 1764-1777.
12. Dionysiou DD, Stamatakos GS, Uzunoglu NK, Nikita KS, Marioli A, (2004) A four-dimensional simulation model of tumour response to radiotherapy in vivo: parametric validation considering radiosensitivity, genetic profile and fractionation. J Theor Biol 230: 1-20.
13. Dionysiou DD, Stamatakos GS, (2006) Applying a 4D multiscale in vivo tumor growth model to the exploration of radiotherapy scheduling: the effects of weekend treatment gaps and p53 gene status on the response of fast growing solid tumors. Cancer Informatics 2: 113-121.
14. Ubezio P, Cameron D, (2008) Cell killing and resistance in pre-operative breast cancer chemotherapy. BMC Cancer 8 Available at: http://www.biomedcentral.com/1471-2407/8/201. Accessed 22 October 2010.
15. Titz B, Jeraj R, (2008) An imaging-based tumour growth and treatment response model: investigating the effect of tumour oxygenation on radiation therapy response. Phys Med Biol 53: 4471-4488.
16. Dionysiou DD, Stamatakos GS, Gintides D, Uzunoglu N, Kyriaki K, (2008) Critical parameters determining standard radiotherapy treatment outcome for glioblastoma multiforme: a computer simulation. Open Biomed Eng J 2: 43-51.
17. Stamatakos GS, Antipas VP, Uzunoglu NK, (2006) A spatiotemporal, patient individualized simulation model of solid tumor response to chemotherapy in vivo: the paradigm of glioblastoma multiforme treated by temozolomide. IEEE Trans Biomed Eng 53: 1467-1477.
18. Anderson AR, Weaver AM, Cummings PT, Quaranta V, (2006) Tumor morphology and phenotypic evolution driven by selective pressure from the Microenvironment. Cell 127: 905-915.
19. Kaste SC, Dome JS, Babyn PS, Graf NM, Grundy P, et al. (2008) Wilms tumour: prognostic factors, staging, therapy and late effects. Pediatr Radiol 38: 2-17.
20. Graf N, Turnade MF, De Kraker J, (2000) The role of preoperative chemotherapy in the management of Wilms' tumor: The SIOP studies. Urologic Clinics of North America 27 (3): 443-454.
21. SIOP: International Society of Paediatric Oncology. Available at: http://www.siop.nl/. Accessed 22 October 2010.
22. GPOH: Society for Paediatric Oncology and Haematology. Available at: http://www.kinderkrebsinfo.de/e2260/index_eng.html. Accessed 22 October 2010.
23. Stamatakos GS, Kolokotroni EA, Dionysiou DD, Georgiadi EC, Desmedt C, (2010) An advanced discrete state-discrete event multiscale simulation model of the response of a solid tumor to chemotherapy: Mimicking a clinical study. J Theor Biol 266 (1): 124-139.
24. Georgiadi EC, Stamatakos GS, Graf NM, Kolokotroni EA, Dionysiou DD, et al. (2008) Multilevel Cancer Modeling in the Clinical Environment: Simulating the Behavior of Wilms Tumor in the Context of the SIOP 2001/GPOH Clinical Trial and the ACGT Project. In: Proceedings of the 8th IEEE International Conference on Bioinformatics and Bioengineering. 8-10 Oct 2008. Athens, Greece. CFP08266, ISBN: 978-1-4244-2845-8, Library of Congress: 2008907441, Paper No. BE-2.1.2.
25. Stamatakos GS, Dionysiou DD, Graf NM, Sofra NA, Desmedt C, et al. (2007) The Oncosimulator: a multilevel, clinically oriented simulation system of tumor growth and organism response to therapeutic schemes. Towards the clinical evaluation of in silico oncology. pp. 6629-6632 In: Proceedings of the 29th Annual International Conference of the IEEE EMBS. 23-26Aug 2007. Lyon, France.
26. Graf N, Hoppe A, Georgiadi E, Belleman R, Desmedt C, et al. (2009) In Silico Oncology for Clinical Decision Making in the Context of Nephroblastoma. Klinische Paediatrie 221: 141-149.
27. Steel GG, (2002) Basic Clinical Radiobiology London Arnold pp. 9-10.
28. Marias K, Dionysiou D, Stamatakos GS, Zacharopoulou F, Georgiadi E, et al. (2007) Multi-level analysis and information extraction considerations for validating 4D models of human function. Lect Notes Comput Sci 4561: 703-709.
29. Lunzer A, Belleman R, Melis P, Pukacki J, Spychała P, et al. (2010) Validating the ACGT oncosimulator with a grid-supported visualisation environment. In: Proceedings 4th International Advanced Research Workshop on In Silico Oncology and Cancer Investigation; 8-9 Sept 2010. Athens, Greece. In press.
30. Beck WT, Cass CE, Houghton PJ, (2000) Microtubule-targeting anticancer drugs derived from plants and microbes: Vinca alkaloids, taxanes and epothilones. In: Bast RC, Kufe DW, Pollock RE, Weichelbaum RR, Holland JF, Frei E, editors. Cancer Medicine 5th ed Hamilton, Ontario, Canada BC Decker.
31. Wood KW, Cornwell WD, Jackson JR, (2001) Past and future of the mitotic spindle as an oncology target. Curr Opin Pharmacol 1 (4): 370-377.
32. Pinkerton CR, McDermott B, Philip T, Biron P, Ardiet C, et al. (1988) Continuous vincristine infusion as part of a high dose chemoradiotherapy regimen: drug kinetics and toxicity. Cancer Chemother Pharmacol 22: 271-274.
33. Kobayashi H, Takemura Y, Holland JF, Ohnuma T, (1998) Vincristine saturation of cellular binding sites and its cytotoxic activity in human lymphoblastic leukaemia cells. Biochem Pharmacol 55: 1229-1234.
34. Salmon SE, Sartorelli AC, (2001) Cancer Chemotherapy. In: Katzung BG, editors. Basic & Clinical Pharmacology International Edition: Lange Medical Books/McGraw-Hill pp. 923-1044.
35. Groninger E, Meeuwsen-de Boer T, Koopmans P, Uges D, Sluiter W, et al. (2002) Pharmacokinetics of Vincristine Monotherapy in Childhood Acute Lymphoblastic Leukemia. Pediatric Research 52: 113-118.
36. Dahl WN, Oftebro R, Pettersen EO, Brustad T, (1976) Inhibitory and cytotoxic effects of Oncovin (Vincristine Sulfate) on cells of human line NHIK 3025. Cancer Res 36: 3101-3105.
37. Sawada K, Noda K, Nakajima H, Shimbara N, Furuichi Y, et al. (2005) Differential cytotoxicity of anticancer agents in pre- and post-immortal lymphoblastoid cell lines. Biol Pharm Bull 28: 1202-1207.
38. Veal GJ, Cole M, Errington J, Parry A, Hale J, et al. (2005) Pharmacokinetics of Dactinomycin in a pediatric patient population: a United Kingdom Children's Cancer Study group study. Clin Cancer Res 11 (16): 5893-5899.
39. Revazova ES, Petrova AS, (1981) Cell cycle and proliferative pool of human tumor strains transplanted into athymic mice. Biull Eksp Biol Med 92: 335-337 (In Russian).
40. Maseide K, Rofstad EK, (2000) Mathematical modeling of chronical hypoxia in tumors considering potential doubling time and hypoxic cell lifetime. Radiother Oncol 54: 171-177.
41. Wein LM, Cohen JE, Wu JT, (2000) Dynamic optimization of a linear-quadratic model with incomplete repair and volume-dependent sensitivity and repopulation. Int J Radiat Oncol Biol Phys 47 (4): 1073-1083.
42. Ribba B, Colin T, Schnell S, (2006) A multiscale mathematical model of cancer, and its use in analyzing irradiation therapies. Theor Biol Med Model 3: 7 doi:10.1186/1742-4682-3-7.
43. Dewey W, Ling CC, Meyn RE, (1995) Radiation-induced apoptosis: relevance to radiotherapy. Int J Radiat Oncol Biol Phys 33 (4): 781-796.
44. Tan TY, Amor DJ, (2006) Tumour surveillance in Beckwith-Wiedermann syndrome and hemihyperplasia: A critical review of the evidence and suggested guidelines for local practice. Journal of Paedeatrics and Child Health 42: 486-490.
45. Shackney SE, McCormack GW, Cuchural GJ, (1978) Growth rate patterns of solid tumours and their relation to responsiveness to therapy. Ann Intern Med 89: 107-121.
46. Craft AW, (1999) Growth rate of Wilms' tumour. The Lancet 354 (9184): 1127.
47. Zoubek A, Slavc I, Mann G, Trittenwein G, Gadner H, (1999) Natural course of a Wilms' tumour. Lancet 354: 344.
48. Carré A, Frantz CN, Weksberg R, Nicholson L, Ciarlo L, et al. (2005) Wilms tumor in an 11-year old with hemihyperplasia. Am J Med Genetics 139A: 165-166.
49. Berrebi D, Leclerc J, Schleiermacher G, Zaccaria I, Boccon-Gibod L, et al. (2008) High cyclin-E staining index in blastemal, stromal or epithelial cells is correlated with tumor aggressiveness in patients with nephroblastoma. PLoS ONE 3 (5): e2216 doi:10.1371/journal.pone.0002216.
50. Gupta PB, Chaffer CL, Weinberg RA, (2009) Cancer stem cells: mirage or reality? Nat Med 15 (9): 1010-1012.
51. Marias K, Sakkalis V, Roniotis A, Farmaki C, Stamatakos G, et al. (2009) Clinically Oriented Translational Cancer Multilevel Modeling: The ContraCancrum project. In: Doessel O, Schlegel WC, editors. pp. 2124-2127 World Congress on Medical Physics and Biomedical Engineering (WC2009), IFMBE Proceedings 25/IV.